RP 3
Alternative Names: RP-3Latest Information Update: 28 Feb 2024
At a glance
- Originator Replimune
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Cytotoxic T-lymphocyte antigen 4 inhibitors; Immunologic cytotoxicity; Membrane glycoprotein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Colorectal cancer
- Phase I Solid tumours
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease) in United Kingdom (Intratumoural)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Monotherapy) in United Kingdom (Intratumoural)
- 29 Dec 2023 Replimune terminated a phase II trial for squamous cell carcinoma (Late-stage disease, Combination therapy, Recurrent, Metastatic disease, Inoperable/Unresectable, First-line therapy) (Intratumoural, Injection) prior to enrollment due to sponsor's decision (NCT05743270)